Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
Bruce D. Cheson, Stephen M. Ansell, Lawrence H. Schwartz, et al.
Blood (2016) Vol. 128, Iss. 21, pp. 2489-2496
Open Access | Times Cited: 436

Showing 1-25 of 436 citing articles:

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Philippe Armand, Andreas Engert, Anas Younes, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 14, pp. 1428-1439
Open Access | Times Cited: 688
Diffuse Large B-Cell Lymphoma
Laurie H. Sehn, Gilles Salles
New England Journal of Medicine (2021) Vol. 384, Iss. 9, pp. 842-858
Open Access | Times Cited: 673
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
Cameron J. Turtle, Kevin A. Hay, Laïla‐Aïcha Hanafi, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 26, pp. 3010-3020
Open Access | Times Cited: 616
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase
Yok‐Lam Kwong, Thomas S. Y. Chan, Daryl Tan, et al.
Blood (2017) Vol. 129, Iss. 17, pp. 2437-2442
Open Access | Times Cited: 442
Hodgkin lymphoma: A review and update on recent progress
Satish Shanbhag, Richard F. Ambinder
CA A Cancer Journal for Clinicians (2017) Vol. 68, Iss. 2, pp. 116-132
Open Access | Times Cited: 428
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
Anas Younes, Patrick Hilden, Bertrand Coiffier, et al.
Annals of Oncology (2017) Vol. 28, Iss. 7, pp. 1436-1447
Open Access | Times Cited: 312
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Alex F. Herrera, Alison J. Moskowitz, Nancy L. Bartlett, et al.
Blood (2017) Vol. 131, Iss. 11, pp. 1183-1194
Open Access | Times Cited: 299
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
Valeria Spina, Alessio Bruscaggin, Annarosa Cuccaro, et al.
Blood (2018) Vol. 131, Iss. 22, pp. 2413-2425
Open Access | Times Cited: 286
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
Radhakrishnan Ramchandren, Eva Domingo‐Domènech, Antonio Rueda, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 23, pp. 1997-2007
Open Access | Times Cited: 222
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study
Thomas S. Uldrick, Priscila Gonçalves, Maher Abdul‐Hay, et al.
JAMA Oncology (2019) Vol. 5, Iss. 9, pp. 1332-1332
Open Access | Times Cited: 198
FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
Yvette L. Kasamon, R. Angelo de Claro, Yaping Wang, et al.
The Oncologist (2017) Vol. 22, Iss. 5, pp. 585-591
Open Access | Times Cited: 182
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
Farrukh T. Awan, Anna Schuh, Jennifer R. Brown, et al.
Blood Advances (2019) Vol. 3, Iss. 9, pp. 1553-1562
Open Access | Times Cited: 170
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
Ranjana H. Advani, Alison J. Moskowitz, Nancy L. Bartlett, et al.
Blood (2021) Vol. 138, Iss. 6, pp. 427-438
Closed Access | Times Cited: 164
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 33, pp. 3081-3089
Open Access | Times Cited: 156
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Stephen M. Ansell, Michael B. Maris, Alexander M. Lesokhin, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 8, pp. 2190-2199
Open Access | Times Cited: 148
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma
Paul J. Bröckelmann, Helen Goergen, Ulrich Keller, et al.
JAMA Oncology (2020) Vol. 6, Iss. 6, pp. 872-872
Open Access | Times Cited: 147
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Elise A. Olsen, Sean Whittaker, Rein Willemze, et al.
Blood (2021) Vol. 140, Iss. 5, pp. 419-437
Open Access | Times Cited: 112
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0
Egesta Lopci, Rodney J. Hicks, Antonia Dimitrakopoulou‐Strauss, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2022) Vol. 49, Iss. 7, pp. 2323-2341
Open Access | Times Cited: 76
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Jennifer L. Crombie, Tara Graff, Lorenzo Falchi, et al.
Blood (2024) Vol. 143, Iss. 16, pp. 1565-1575
Open Access | Times Cited: 48
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
Jaroslav Žák, Isaraphorn Pratumchai, Brett S. Marro, et al.
Science (2024) Vol. 384, Iss. 6702
Closed Access | Times Cited: 43
Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments
Katja Pinker, Christopher C. Riedl, Wolfgang Weber
European Journal of Nuclear Medicine and Molecular Imaging (2017) Vol. 44, Iss. S1, pp. 55-66
Open Access | Times Cited: 142
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Yuqin Song, Quanli Gao, Huilai Zhang, et al.
Leukemia (2019) Vol. 34, Iss. 2, pp. 533-542
Open Access | Times Cited: 139
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
Philipp B. Staber, Marco Herling, Mar Bellido, et al.
Blood (2019) Vol. 134, Iss. 14, pp. 1132-1143
Open Access | Times Cited: 123
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma
Pamela B. Allen, Hatice Savas, Andrew M. Evens, et al.
Blood (2020) Vol. 137, Iss. 10, pp. 1318-1326
Open Access | Times Cited: 122
FDG‐PET/CT in the management of lymphomas: current status and future directions
Tarec Christoffer El‐Galaly, Diego Villa, Lars Christian Gormsen, et al.
Journal of Internal Medicine (2018) Vol. 284, Iss. 4, pp. 358-376
Open Access | Times Cited: 112
Page 1 - Next Page

Scroll to top